Recombinant Human Insulin-like Growth Factor as a Therapeutic Agent for Severe Insulin Resistance and Type II Diabetes Mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue Supplement, 1997, Pages 123-130

  Moses, Alan C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

diabetes mellitus; insulin resistance; rhIGF I

Indexed keywords

INSULIN; LIPID; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; TRIACYLGLYCEROL;

CONFERENCE PAPER; DOSE RESPONSE; DRUG TOLERABILITY; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; SEQUENCE HOMOLOGY;

EID: 0030957298     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.1997.10.S1.123     Document Type: Article

References (32)

1. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988; 81: 976-981.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
3. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995; 310: 83-88.
4. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137-140.
5. Zenobi PD, Graf S, Ursprung H, Froesch ER. Effects of recombinant insulin-like growth factor I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 1992; 89: 1908-1913.
6. Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minaker KL. Miles JM, Rubenstein AH, Vandepol CJ, et al. Effects of recombinant human IGF-I on glucose and lcucine kinetics in men. Am J Physiol 1993; 265: E831-838.
7. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Acute effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992; 262: E130-133.
8. Van Schravendijk CFH, Heylcn L, Van den Brande JL, Pipeleers DG. Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic beta cells. Diabetologia 1990; 33: 649-653.
9. Leahy JL, Vanderkerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 1990; 126: 1593-1598.
10. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-2256.
11. Tan K, Baxter RC. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986; 63: 651-655.
12. Tamborlane WV, Hintz RL, Bergman M. Genel M. Felig P, Sherwin RS. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303-307.
13. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA Effect of insulin on the insulin-ike growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1312-1317.
14. Clayton KL, Holly JM, Carlsson LM, Jones J, Cheetham TD, Taylor AM, Dunger DB. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1994; 41: 517-524.
15. Dohm GL, Elton CW, Raju MS, Moonev ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson SM Jr., Caro JF. IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 1990; 39: 1028-1032.
16. Schoenle EJ, Zenobi PD,Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991; 34; 675-679.
17. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome [letter]. N Engl J Med 1990; 323: 1425-1426.
18. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205-210.
19. Reaven GM, Farquhar JW. Steady state plasma insulin response to continuous glucose infusion in normal and diabetic subjects. Diabetes 1969; 18: 273-279.
20. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28 (Suppl): S185-194.
21. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, et al. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696-705.
22. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
23. Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563-1568.
24. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91-100.
25. rhIGF-I in NIDDM Study Group. Evidence from a dose-ranging study that recombinant insulin-like growth factor I (rhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM). Diabetes 1996; 45 (Suppl 2 - Abstract 94): 27A.
26. Bergman RN, Finegold DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6: 45-86.
27. Reaven GM. Insulin resistance and its consequences: Non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus, A Fundamental and Clinical Text. Philadelphia. PA: Lippincott-Raven. 1996; 509-518.
28. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, Froesch ER. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I [see comments]. Diabetologia 1993; 36: 465-469.
29. Lieberman SA, Bukar J, Chen SA, Celniker AC, Compton PG, Cook J, Albu J, Perlman AJ, Hoffman AR. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. J Clin Endocrinol Metab 1992; 75: 30-36.
30. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369-374.
31. Usala AL, Madigan T, Burguera B, Cefalu W, Sinha MK, Powell JG, Usala SJ. High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 435-440.
32. rhIGF-I in Non-Insulin Dependent Diabetes Study (RINDS) Group. Safety profiling of rhIGF-I therapy in patients with NIDDM: A dose-ranging, placebo control trial. Diabetes 1996, 45 (Suppl 2 - Abstract 254): 71A.